Fate Therapeutics, Inc. - Common Stock — Cash Flow (NASDAQ:FATE) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -39.23 M-162.87 M-248.21 M-132.26 M-122.87 M-106.08 M -103.1 M Cash from investing activities -161.08 M-324.02 M166.75 M112.67 M12.22 M111.17 M 92.08 M Cash from financing activities 282.84 M453.13 M9.21 M85 K99.89 M5.49 M — Free cash flow -39.23 M-162.87 M-248.21 M-132.26 M-122.87 M-112.04 M -108.09 M

News

Wall Street Lunch: BP Slips After Ousting Chairman Albert Manifold Over Governance Concern

5 Healthcare Stocks Set to Join the Russell 3000 - TipRanks.com

Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates

CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates

Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Novavax (NVAX) Reports Q1 Loss, Beats Revenue Estimates

Fate Therapeutics at Leerink Global Healthcare Conference: Strategic Shift in Focus

Baird reiterates Fate Therapeutics stock rating on trial progress

Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates

Fate Therapeutics earnings beat, revenue topped estimates

Fate Therapeutics reports positive lupus treatment data at ASH meeting

Fate Therapeutics earnings beat by $0.03, revenue topped estimates